drugset
drugset / Trial / NCT04072354

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

NCT04072354 ↗

Phase 3 Completed 463 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who have been diagnosed with schizophrenia.

Timeline

Start
2019-09-17
Primary completion
2023-05-12
Completion
2023-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulotaront Small molecule 50 mg —
Subject Ulotaront Small molecule 75 mg —

Indications

schizophrenia